Page last updated: 2024-10-16

carbamates and Cancer of Liver

carbamates has been researched along with Cancer of Liver in 63 studies

Research Excerpts

ExcerptRelevanceReference
" Areas covered: This review covers the preclinical and clinical development of sofosbuvir/velpatasvir (SOF/VEL), an interferon-free, once daily, pangenotypic treatment for the treatment of chronic hepatitis C virus (HCV) infection."8.95A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection. ( Jacobson, IM; Weisberg, IS, 2017)
"This prospective study was conducted on a real word cohort of 1562 treatment naïve chronic hepatitis C (CHC) Egyptian patients, who received 12-weeks therapy with sofosbuvir (SOF) plus daclatasvir (DCV) ± ribavirin (RBV)."7.96Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. ( Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH, 2020)
" The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin."7.88Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. ( Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M, 2018)
"We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)."7.83Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016)
"The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC)."7.81Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. ( Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y, 2015)
"The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients."5.46The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. ( Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M, 2017)
" Areas covered: This review covers the preclinical and clinical development of sofosbuvir/velpatasvir (SOF/VEL), an interferon-free, once daily, pangenotypic treatment for the treatment of chronic hepatitis C virus (HCV) infection."4.95A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection. ( Jacobson, IM; Weisberg, IS, 2017)
"In this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg)."3.96Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study. ( Guyader, D; Jézéquel, C; Lalanne, S; Lemaitre, F; Mercerolle, M; Pronier, C; Tron, C; Verdier, MC, 2020)
"This prospective study was conducted on a real word cohort of 1562 treatment naïve chronic hepatitis C (CHC) Egyptian patients, who received 12-weeks therapy with sofosbuvir (SOF) plus daclatasvir (DCV) ± ribavirin (RBV)."3.96Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. ( Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH, 2020)
" The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin."3.88Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. ( Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M, 2018)
" The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV/PTV/r+DSV for 12 weeks."3.88Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice. ( Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M, 2018)
"We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)."3.83Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016)
"The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC)."3.81Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. ( Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y, 2015)
" The patient received since four years pyridinolcarbamate (Prodectin) because of obliterating peripheral arteriosclerosis."3.67[Pyridimocarbamate (prodectin)-induced acute liver damage, cirrhosis and primary liver cancer--accidental finding?]. ( Kendrey, G; Kiss, F; László, B, 1989)
"Liver malignant tumors (LMTs) represent a serious adverse drug event associated with drug-induced liver injury."1.62Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions. ( Kurosaki, K; Uesawa, Y, 2021)
"He died 3 months after the abrupt recurrence."1.56Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report. ( Arai, J; Fukumura, Y; Imai, M; Kato, J; Kojima, K; Kondo, M; Kurokawa, K; Mori, M; Ohki, T; Seki, M; Shibata, C; Tagawa, K; Takagi, K; Toda, N, 2020)
"Furthermore, hepatocellular carcinoma (HCC) is known to dedifferentiate from hypovascular tumors, such as dysplastic nodules or well-differentiated HCC, to hypervascular tumors."1.56Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals. ( Fujisaki, K; Hashiguchi, M; Hiramine, Y; Hori, T; Ido, A; Ijuin, S; Imanaka, D; Inada, Y; Kanmura, S; Kumagai, K; Kure, T; Mawatari, S; Moriuchi, A; Oda, K; Saisyoji, A; Sakae, H; Sakurai, K; Tabu, K; Tamai, T; Taniyama, O; Toyodome, A; Uto, H, 2020)
"SOF/VEL/VOX is an effective and safe retreatment for patients with HCV who have failed on a previous DAA course in a real-life setting."1.51Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. ( Aghemo, A; Alberti, A; Bonfanti, P; Carolo, G; Carriero, C; Centenaro, R; Degasperi, E; Fabris, P; Faggiano, G; Fagiuoli, S; Gatti, F; Giorgini, A; Grossi, G; Lampertico, P; Landonio, S; Lombardi, A; Lomonaco, L; Maggiolo, F; Noventa, F; Paolucci, S; Paon, V; Pasin, F; Pasulo, L; Pozzoni, P; Puoti, M; Romano, A; Rossi, MC; Rovere, P; Russo, FP; Soffredini, R; Soria, A; Spinetti, A; Vario, A; Vinci, M; Zoncada, A, 2019)
"Data are sparse on treatment of chronic hepatitis C virus (HCV) in cancer patients."1.51Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. ( Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA, 2019)
"Ascites and hepatic encephalopathy occurred in 10."1.48High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. ( Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M, 2018)
"The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients."1.46The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. ( Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M, 2017)
"At the age of 46, he was diagnosed with hepatocellular carcinoma with subsequent resection of the tumour in May 2015."1.46Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation. ( Rostkowska, K; Simon, K; Szymanek-Pasternak, A, 2017)
" Details of serious adverse events (SAEs) were recorded."1.46Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. ( Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J, 2017)
"In all, 14 patients developed hepatocellular carcinoma during follow-up, and the development rate per 1,000 person-years was 7."1.43Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. ( Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y, 2016)
"Amprenavir was able to delay the growth of hepatocarcinoma xenografts in nude mice and had a synergistic effect with Doxorubicin."1.39Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. ( Baldi, A; Chirianni, A; De Luca, A; Esposito, V; Galati, R; Manente, L; Montesarchio, V; Pagliano, P; Parrella, G; Parrella, R; Spugnini, EP; Verdina, A; Viglietti, R, 2013)
" Future investigation should address the possible hepatocarcinogenicity of pesticides using biomarkers of exposure and other techniques to better estimate dose-response relationships."1.33Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. ( Abdel-Hamid, A; Abdel-Hamid, M; Eissa, SA; El-Ghorory, L; Ezzat, S; Hifnawy, T; Labib, NA; Loffredo, CA; Mikhail, NN; Mokhtar, N; Strickland, GT, 2005)

Research

Studies (63)

TimeframeStudies, this research(%)All Research%
pre-199017 (26.98)18.7374
1990's1 (1.59)18.2507
2000's1 (1.59)29.6817
2010's31 (49.21)24.3611
2020's13 (20.63)2.80

Authors

AuthorsStudies
Turgeon, MK1
Shah, SA1
Delman, AM1
Tran, BV1
Agopian, VG1
Wedd, JP1
Magliocca, JF1
Kim, A1
Cameron, A1
Olyaei, A1
Orloff, SL1
Anderson, MP1
Kubal, CA1
Cannon, RM1
Locke, JE1
Simpson, MA1
Akoad, ME1
Wongjirad, CP1
Emamaullee, J1
Moro, A1
Aucejo, F1
Feizpour, CA1
Vagefi, PA1
Nguyen, MH1
Esquivel, CO1
Dhanireddy, K1
Subramanian, V1
Chavarriaga, A1
Kazimi, MM1
Anderson, MS1
Sonnenday, CJ1
Kim, SC1
Foley, DP1
Abdouljoud, M1
Salgia, RJ1
Moris, D1
Sudan, DL1
Ganesh, SR1
Humar, A1
Doyle, M1
Chapman, WC1
Maithel, SK1
Ghanm, SE1
Shebl, NA1
El Sayed, IET1
Abdel-Bary, HM1
Saad, BF1
Othman Saad, W1
Yoo, HW1
Park, JY1
Kim, SG1
Jung, YK1
Lee, SH1
Kim, MY1
Jun, DW1
Jang, JY1
Lee, JW1
Kwon, OS1
Degasperi, E2
Spinetti, A1
Lombardi, A1
Landonio, S1
Rossi, MC1
Pasulo, L1
Pozzoni, P1
Giorgini, A2
Fabris, P1
Romano, A1
Lomonaco, L1
Puoti, M2
Vinci, M1
Gatti, F1
Carolo, G1
Zoncada, A1
Bonfanti, P1
Russo, FP1
Aghemo, A2
Soria, A1
Centenaro, R1
Maggiolo, F1
Rovere, P1
Pasin, F1
Paon, V1
Faggiano, G1
Vario, A1
Grossi, G1
Soffredini, R1
Carriero, C1
Paolucci, S1
Noventa, F1
Alberti, A1
Lampertico, P2
Fagiuoli, S1
Merli, M1
Rossotti, R1
Travi, G1
Ferla, F1
Lauterio, A1
Angelini Zucchetti, T1
Alcantarini, C1
Bargiacchi, O1
De Carlis, L1
Ngo, P1
Bycroft, R1
Brustolin, L1
Pettenuzzo, N1
Nardon, C1
Quarta, S1
Marchiò, L1
Biondi, B1
Pontisso, P1
Fregona, D1
Holmes, JA1
Chung, RT1
Junger, H1
Knoppke, B1
Weigand, K1
Evert, K1
Brennfleck, FW1
Melter, M1
Schlitt, HJ1
Brunner, SM1
Lalanne, S1
Jézéquel, C1
Tron, C1
Verdier, MC1
Mercerolle, M1
Pronier, C1
Guyader, D1
Lemaitre, F1
Tayyab, GUN1
Rasool, S1
Nasir, B1
Rubi, G1
Abou-Samra, AB1
Butt, AA1
Kurokawa, K1
Ohki, T1
Kato, J1
Fukumura, Y1
Imai, M1
Shibata, C1
Arai, J1
Kondo, M1
Takagi, K1
Kojima, K1
Seki, M1
Mori, M1
Toda, N1
Tagawa, K1
Tabu, K1
Mawatari, S1
Oda, K1
Kumagai, K1
Inada, Y1
Uto, H1
Saisyoji, A1
Hiramine, Y1
Hashiguchi, M1
Tamai, T1
Hori, T1
Fujisaki, K1
Imanaka, D1
Kure, T1
Taniyama, O1
Toyodome, A1
Ijuin, S1
Sakae, H1
Sakurai, K1
Moriuchi, A1
Kanmura, S1
Ido, A1
Chan, J1
Kim, JJ1
Barrett, BK1
Hamadeh, A1
Feld, JJ1
Wong, WWL1
Cheng, TS1
Liang, PC1
Huang, CF1
Yeh, ML1
Huang, CI1
Lin, ZY1
Chen, SC1
Huang, JF1
Dai, CY1
Hsieh, PH1
Chuang, WL1
Yu, ML1
Elsadek, HM1
Abdelbaser, ES1
Emara, MH1
Soliman, HH1
Farag, AA1
Kurosaki, K1
Uesawa, Y1
Shimizu, H1
Matsui, K1
Iwabuchi, S1
Fujikawa, T1
Nagata, M1
Takatsuka, K1
Tanemura, H1
Nakazaki, H1
Nakano, M1
Watanabe, T1
Britto, K1
Cheung, W1
Cameron, R1
Roberts, SK1
Kemp, W1
Nagaoki, Y1
Imamura, M1
Aikata, H1
Daijo, K1
Teraoka, Y1
Honda, F1
Nakamura, Y1
Hatooka, M1
Morio, R1
Morio, K1
Kan, H1
Fujino, H1
Kobayashi, T1
Masaki, K1
Ono, A1
Nakahara, T1
Kawaoka, T1
Tsuge, M1
Hiramatsu, A1
Kawakami, Y1
Hayes, CN1
Miki, D1
Ochi, H1
Chayama, K1
Szymanek-Pasternak, A1
Rostkowska, K1
Simon, K2
Ida, H1
Hagiwara, S1
Kono, M1
Minami, T1
Chishina, H1
Arizumi, T1
Takita, M1
Yada, N1
Minami, Y1
Ueshima, K1
Nishida, N1
Kudo, M2
Beinhardt, S1
Al-Zoairy, R1
Kozbial, K1
Stättermayer, AF1
Maieron, A1
Stauber, R1
Strasser, M1
Zoller, H1
Graziadei, I1
Rasoul-Rockenschaub, S1
Trauner, M1
Ferenci, P1
Hofer, H1
Bittermann, T1
Weinberg, E1
Persico, M1
Aglitti, A1
Rendina, M1
Lleo, A1
Ciancio, A1
Di Marco, V1
Brunetto, MR1
Zuin, M1
Andreone, P2
Villa, E1
Troshina, G1
Calvaruso, V1
Coco, B1
Conti, F1
Di Leo, A1
Marzi, L1
Boccaccio, V1
Bollani, S1
Maisonneuve, P1
Bruno, S1
Hassany, M1
Elsharkawy, A1
Maged, A1
Mehrez, M1
Asem, N1
Gomaa, A1
Mostafa, Z1
Abbas, B1
Soliman, M1
Esmat, G1
Flisiak, R1
Janczewska, E1
Łucejko, M1
Karpińska, E1
Zarębska-Michaluk, D1
Nazzal, K1
Bolewska, B1
Białkowska, J1
Berak, H1
Fleischer-Stępniewska, K1
Tomasiewicz, K1
Karwowska, K1
Piekarska, A1
Tronina, O1
Tuchendler, E1
Garlicki, A1
Revuelta-Herrero, JL1
Giménez-Manzorro, A1
Matilla-Peña, A1
Herranz-Alonso, A1
Sanjurjo-Sáez, M1
Torres, HA1
Economides, MP1
Angelidakis, G1
Hosry, J1
Kyvernitakis, A1
Mahale, P1
Jiang, Y1
Miller, E1
Blechacz, B1
Naing, A1
Samaniego, F1
Kaseb, A1
Raad, II1
Granwehr, BP1
Preda, CM1
Baicus, C1
Sandra, I1
Oproiu, A1
Manuc, T1
Constantinescu, I1
Gavrila, D1
Diculescu, M1
Dumitru, R1
Vasilescu, C1
Tieranu, C1
Istratescu, D1
Voiosu, T1
Manuc, M1
Li, YP1
Ramirez, S1
Humes, D1
Jensen, SB1
Gottwein, JM1
Bukh, J1
Gamal, N1
Vitale, G1
Horváth, G1
Halász, T1
Makara, M1
Hunyady, B1
Sugimoto, K1
Kim, SR1
Kim, SK1
Imoto, S1
Tohyama, M1
Kim, KI1
Ohtani, A1
Hatae, T1
Yano, Y1
Hayashi, Y1
Krastev, Z1
Jelev, D1
Antonov, K1
Petkova, T1
Atanasova, E1
Zheleva, N1
Tomov, B1
Boyanova, Y1
Mateva, L1
Saab, S2
Parisé, H2
Virabhak, S2
Wang, A2
Marx, SE1
Sanchez Gonzalez, Y1
Misurski, D2
Johnson, S2
Gonzalez, YS1
Juday, T1
Nagata, H1
Nakagawa, M1
Nishimura-Sakurai, Y1
Asano, Y1
Tsunoda, T1
Miyoshi, M1
Kaneko, S1
Goto, F1
Otani, S1
Kawai-Kitahata, F1
Murakawa, M1
Nitta, S1
Itsui, Y1
Azuma, S1
Kakinuma, S1
Tojo, N1
Tohda, S1
Asahina, Y1
Watanabe, M1
Akuta, N1
Kobayashi, M2
Suzuki, F1
Sezaki, H1
Fujiyama, S1
Kawamura, Y1
Hosaka, T1
Saitoh, S1
Suzuki, Y1
Arase, Y1
Ikeda, K1
Kumada, H1
Hachicha, M1
Botta-Fridlund, D1
Weisberg, IS1
Jacobson, IM1
Calleja, JL1
Crespo, J1
Rincón, D1
Ruiz-Antorán, B1
Fernandez, I1
Perelló, C1
Gea, F1
Lens, S1
García-Samaniego, J1
Sacristán, B1
García-Eliz, M1
Llerena, S1
Pascasio, JM1
Turnes, J1
Torras, X1
Morillas, RM1
Llaneras, J1
Serra, MA1
Diago, M1
Rodriguez, CF1
Ampuero, J1
Jorquera, F1
Simon, MA1
Arenas, J1
Navascues, CA1
Bañares, R1
Muñoz, R1
Albillos, A1
Mariño, Z1
Shen, Y1
Lv, D1
Wang, J1
Yin, Y1
Miao, F1
Dou, F1
Zhang, J1
Esposito, V1
Verdina, A1
Manente, L1
Spugnini, EP1
Viglietti, R1
Parrella, R1
Pagliano, P1
Parrella, G1
Galati, R1
De Luca, A1
Baldi, A1
Montesarchio, V1
Chirianni, A1
FALKSON, G1
FALKSON, HC1
Ezzat, S1
Abdel-Hamid, M1
Eissa, SA1
Mokhtar, N1
Labib, NA1
El-Ghorory, L1
Mikhail, NN1
Abdel-Hamid, A1
Hifnawy, T1
Strickland, GT1
Loffredo, CA1
Lawson, D1
Paik, WK1
Morris, HP1
Weinhouse, S1
Pound, AW3
Lawson, TA1
Elias, EG1
Band, PR1
Mittelman, A1
Colsky, J1
Regelson, W1
Shnider, BI1
Hanley, JA1
Weisburger, EK1
Ulland, BM1
Schueler, RL1
Weisburger, JH1
Harris, PN1
Pereira, MA1
Khoury, MM1
Glauert, HP1
Davis, RA1
Kendrey, G1
Kiss, F1
László, B1
Richardson, UI1
Snodgrass, PJ1
Nuzum, CT1
Tashjian, AH1
Mirvish, SS1
Bhide, SV1
De Luca, C1
Valls, GB1
Mason, JA1
Sweeney, MJ1
Hoffman, DH1
Poore, GA1
Gailani, S1
Blais, M1
Tatibana, M1
Shigesada, K1
Hoogenraad, NJ1
Lee, DC1
Sillero, J1
De Cañete, F1
Moreno Quesada, A1
Salido Sánchez, A1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Regression of Liver Fibrosis Assessed by Transient Elastography After Daclatasvir and Asunaprevir Combined Treatment in Advanced Fibrotic/Cirrhotic Patients With Chronic Hepatitis C Genotype 1b Infection[NCT02865369]103 participants (Anticipated)Observational [Patient Registry]2016-09-30Not yet recruiting
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC[NCT02771405]Phase 3150 participants (Anticipated)Interventional2016-03-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

6 reviews available for carbamates and Cancer of Liver

ArticleYear
New approaches in viraemic organ transplantation and antiviral therapies.
    Nature reviews. Gastroenterology & hepatology, 2020, Volume: 17, Issue:2

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guani

2020
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.
    Expert review of anti-infective therapy, 2015, Volume: 13, Issue:3

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Clinical Trials,

2015
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
    Orvosi hetilap, 2015, May-24, Volume: 156, Issue:21

    Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clini

2015
A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:5

    Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Genotype; Hepacivirus; H

2017
The carcinogenic action and metabolism of urethan and N-hydroxyurethan.
    Advances in cancer research, 1968, Volume: 11

    Topics: Adenoma; Animals; Animals, Newborn; Body Fluids; Breast Neoplasms; Carbamates; Carcinogens; Carcinom

1968
Two carbamyl phosphate synthetases of mammals: specific roles in control of pyrimidine and urea biosynthesis.
    Advances in enzyme regulation, 1972, Volume: 10

    Topics: Adenosine Triphosphate; Animals; Arginine; Aspartic Acid; Carbamates; Carbon Isotopes; Carcinoma, He

1972

Trials

2 trials available for carbamates and Cancer of Liver

ArticleYear
Clinical evaluation of two weekly dose schedules of 'IC-140'. 4-N, N-bis (2-Chloroethyl) amino phenyl N (P-carboxyphenyl) carbamate, in the treatmentment of solid tumors 1,2.
    Oncology, 1975, Volume: 31, Issue:5-6

    Topics: Adenocarcinoma; Breast Neoplasms; Carbamates; Clinical Trials as Topic; Drug Administration Schedule

1975
Clinical trial of acetylenic carbamate: 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NSC-112682).
    Cancer chemotherapy reports, 1970, Volume: 54, Issue:3

    Topics: Adolescent; Adult; Aged; Alkynes; Antineoplastic Agents; Carbamates; Carcinoma, Bronchogenic; Carcin

1970

Other Studies

55 other studies available for carbamates and Cancer of Liver

ArticleYear
Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Annals of surgery, 2021, 10-01, Volume: 274, Issue:4

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Administration S

2021
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
    Asian Pacific journal of cancer prevention : APJCP, 2021, Oct-01, Volume: 22, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Ascites; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combina

2021
Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
    Scientific reports, 2022, 01-07, Volume: 12, Issue:1

    Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, C

2022
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Journal of hepatology, 2019, Volume: 71, Issue:6

    Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Resistance, Viral;

2019
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
    Transplant infectious disease : an official journal of the Transplantation Society, 2019, Volume: 21, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Res

2019
Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
    BMJ case reports, 2019, Sep-16, Volume: 12, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Humans; Liver Neoplasms;

2019
Au(iii)-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells.
    Dalton transactions (Cambridge, England : 2003), 2019, Nov-14, Volume: 48, Issue:42

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carbamates; Carcinoma, Hepatocellular; Cell Li

2019
Living Donor Liver Transplantation From Hepatitis C-Infected Donor to Hepatitis C-Infected Recipient.
    Hepatology (Baltimore, Md.), 2020, Volume: 72, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Child; Fatty Liver; Female; Hepacivirus; Hepatectomy; Hepatitis

2020
Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.
    Therapeutic drug monitoring, 2020, Volume: 42, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Dr

2020
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
    BMC gastroenterology, 2020, Apr-06, Volume: 20, Issue:1

    Topics: Adult; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; G

2020
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
    Journal of medical case reports, 2020, May-27, Volume: 14, Issue:1

    Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Fatal Outcome; Hepacivirus; Hepatitis

2020
Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    PloS one, 2020, Volume: 15, Issue:8

    Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Female; Genotype;

2020
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
    Journal of viral hepatitis, 2021, Volume: 28, Issue:2

    Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Genotype; Hepaciviru

2021
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    The Kaohsiung journal of medical sciences, 2021, Volume: 37, Issue:4

    Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Com

2021
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    European journal of gastroenterology & hepatology, 2020, Volume: 32, Issue:8

    Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus

2020
Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions.
    Biomolecules, 2021, 06-25, Volume: 11, Issue:7

    Topics: Adverse Drug Reaction Reporting Systems; Carbamates; Chemical and Drug Induced Liver Injury; Databas

2021
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017, Volume: 36, Issue:3

    Topics: Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular;

2017
Hepatobiliary and Pancreatic: Rare vascular tumor following treatment for hepatitis C with direct-acting antivirals.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:12

    Topics: Aged, 80 and over; Antiviral Agents; Carbamates; Fatal Outcome; Female; Hemangioendothelioma, Epithe

2017
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therap

2017
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
    BMJ case reports, 2017, Sep-15, Volume: 2017

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; D

2017
Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Digestive diseases (Basel, Switzerland), 2017, Volume: 35, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatoc

2017
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:7

    Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy

2018
Complete Response of Diffuse Large B Cell Lymphoma After Direct-Acting Antiviral Therapy for Hepatitis C Virus.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, Volume: 17, Issue:5

    Topics: Aged; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; H

2019
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:12

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug

2018
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:8

    Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Fem

2018
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:11

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyc

2018
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
    Journal of clinical pharmacy and therapeutics, 2018, Volume: 43, Issue:6

    Topics: 2-Naphthylamine; Aged; Anilides; Antineoplastic Agents; Antiviral Agents; Carbamates; Carcinoma, Hep

2018
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
    The American journal of gastroenterology, 2019, Volume: 114, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Dru

2019
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
    United European gastroenterology journal, 2019, Volume: 7, Issue:5

    Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembol

2019
Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Gastroenterology, 2014, Volume: 146, Issue:3

    Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Genotyp

2014
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
    Oncology, 2015, Volume: 89 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatoc

2015
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
    World journal of gastroenterology, 2016, Feb-28, Volume: 22, Issue:8

    Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropa

2016
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Journal of medical economics, 2016, Volume: 19, Issue:8

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbama

2016
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Advances in therapy, 2016, Volume: 33, Issue:8

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocel

2016
Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
    Hepatology international, 2016, Volume: 10, Issue:6

    Topics: Antigens, Neoplasm; Antiviral Agents; Biomarkers, Tumor; Carbamates; Carcinoma, Hepatocellular; Carr

2016
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Oncology, 2016, Volume: 91, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Carcinoma, Hepatocell

2016
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
    Nephrologie & therapeutique, 2016, Volume: 12, Issue:7

    Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Hum

2016
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Journal of hepatology, 2017, Volume: 66, Issue:6

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbama

2017
GSI-I has a better effect in inhibiting hepatocellular carcinoma cell growth than GSI-IX, GSI-X, or GSI-XXI.
    Anti-cancer drugs, 2012, Volume: 23, Issue:7

    Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Fa

2012
Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts.
    Journal of cellular physiology, 2013, Volume: 228, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carbamates; Carcinoma, Hepatocel

2013
CLINICAL EVALUATION OF BIS(2-CHLOROPROPYL)CARBAMIC ACID, ETHYL ESTER (6W54, NSC-53105).
    Cancer chemotherapy reports, 1964, Volume: 36

    Topics: Agranulocytosis; Antineoplastic Agents; Biomedical Research; Bone Marrow Diseases; Breast Neoplasms;

1964
Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt.
    International journal of hygiene and environmental health, 2005, Volume: 208, Issue:5

    Topics: Adult; Carbamates; Carcinoma, Hepatocellular; Case-Control Studies; Egypt; Environmental Exposure; F

2005
Carbamyl phosphate synthetases in rat liver neoplasms.
    Cancer research, 1975, Volume: 35, Issue:1

    Topics: Animals; Carbamates; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cell Division; Cell Fractionat

1975
Carcinogenesis by carbamic acid esters and their binding to DNA.
    Cancer research, 1976, Volume: 36, Issue:3

    Topics: Adenoma; Animals; Carbamates; Carcinoma, Hepatocellular; Croton Oil; Esters; Hemangioma; Leukemia, E

1976
Carcinogenicity of three dose levels of 1,4-Bis(4-fluorophenyl)-2-propynyl-N-cyclooctyl carbamate in male Sprague-Dawley and F344 rats.
    Journal of the National Cancer Institute, 1975, Volume: 54, Issue:4

    Topics: Adenocarcinoma; Animals; Carbamates; Carcinogens; Colonic Neoplasms; Diet; Ear Neoplasms; Genotype;

1975
Screen of five alkyl carbamates for initiating and promoting activity in rat liver.
    Cancer letters, 1991, Volume: 57, Issue:1

    Topics: Animals; Carbamates; Carcinogenicity Tests; Carcinogens; Diethylnitrosamine; gamma-Glutamyltransfera

1991
[Pyridimocarbamate (prodectin)-induced acute liver damage, cirrhosis and primary liver cancer--accidental finding?].
    Morphologiai es igazsagugyi orvosi szemle, 1989, Volume: 29, Issue:1

    Topics: Acute Disease; Arteriosclerosis; Carbamates; Chemical and Drug Induced Liver Injury; Female; Humans;

1989
Establishment of a clonal strain of hepatoma cells which maintain in culture the five enzymes of the urea cycle.
    Journal of cellular physiology, 1974, Volume: 83, Issue:1

    Topics: Ammonia; Animals; Arginase; Arginine; Bucladesine; Carbamates; Carcinoma, Hepatocellular; Chromosome

1974
Comparative study of metabolic profiles of primary hepatoma, regenerating liver, and liver in newborn Swiss mice.
    Journal of the National Cancer Institute, 1971, Volume: 47, Issue:4

    Topics: Acetates; Aldehyde-Lyases; Amides; Animals; Animals, Newborn; Aspartic Acid; Carbamates; Carcinoma,

1971
Drug effects on catalase activity in the mammalian cell. The role of the cell in drug action.
    Biochemical pharmacology, 1970, Volume: 19, Issue:7

    Topics: Acetamides; Aerobiosis; Alkenes; Allyl Compounds; Amides; Animals; Carbamates; Carcinoma; Carcinoma,

1970
Enzymes in pyrimidine biosynthesis.
    Advances in enzyme regulation, 1970, Volume: 9

    Topics: Amidohydrolases; Animals; Carbamates; Carcinoma, Hepatocellular; Fasting; Liver; Liver Neoplasms; Li

1970
Effect of uridine on de novo pyrimidine biosynthesis in rat hepatoma cells in culture.
    The Journal of biological chemistry, 1974, May-10, Volume: 249, Issue:9

    Topics: Amidohydrolases; Animals; Aspartate Carbamoyltransferase; Carbamates; Carbon Dioxide; Carbon Radiois

1974
[Functioning malignant carcinoid (case report. Preliminary results of treatment with 3 new drugs)].
    Revista clinica espanola, 1969, Nov-30, Volume: 115, Issue:4

    Topics: Biopsy; Carbamates; Carcinoid Tumor; Cycloheptanes; Female; Histamine H1 Antagonists; Humans; Liver

1969
Tumour formation in mice by urethane administered with related carbamates.
    British journal of cancer, 1972, Volume: 26, Issue:3

    Topics: Animals; Carbamates; Carcinoma; Carcinoma, Squamous Cell; Croton Oil; Drug Interactions; Esters; Inj

1972
Carcinogenesis and cell proliferation.
    The New Zealand medical journal, 1968, Volume: 67, Issue:426

    Topics: Acetates; Animals; Carbamates; Croton Oil; Hepatectomy; Liver Neoplasms; Mice; Neoplasms, Experiment

1968